ATE247713T1 - Verfahren zur herstellung von rekombinanten plasmiden - Google Patents

Verfahren zur herstellung von rekombinanten plasmiden

Info

Publication number
ATE247713T1
ATE247713T1 AT96933294T AT96933294T ATE247713T1 AT E247713 T1 ATE247713 T1 AT E247713T1 AT 96933294 T AT96933294 T AT 96933294T AT 96933294 T AT96933294 T AT 96933294T AT E247713 T1 ATE247713 T1 AT E247713T1
Authority
AT
Austria
Prior art keywords
cells
genetic material
plasmids
culture system
toxic
Prior art date
Application number
AT96933294T
Other languages
German (de)
English (en)
Inventor
Mohamad A Morsey
Original Assignee
Novartis Pharma Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Pharma Gmbh filed Critical Novartis Pharma Gmbh
Application granted granted Critical
Publication of ATE247713T1 publication Critical patent/ATE247713T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/67—General methods for enhancing the expression

Landscapes

  • Genetics & Genomics (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)
AT96933294T 1995-10-17 1996-10-17 Verfahren zur herstellung von rekombinanten plasmiden ATE247713T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US54805995A 1995-10-17 1995-10-17
US56497395A 1995-11-30 1995-11-30
PCT/CA1996/000693 WO1997014805A2 (en) 1995-10-17 1996-10-17 Methods for production of recombinant plasmids

Publications (1)

Publication Number Publication Date
ATE247713T1 true ATE247713T1 (de) 2003-09-15

Family

ID=27068752

Family Applications (1)

Application Number Title Priority Date Filing Date
AT96933294T ATE247713T1 (de) 1995-10-17 1996-10-17 Verfahren zur herstellung von rekombinanten plasmiden

Country Status (9)

Country Link
US (1) US5922583A (2)
EP (1) EP0856059B1 (2)
JP (1) JPH11513562A (2)
AT (1) ATE247713T1 (2)
AU (1) AU7208896A (2)
CA (1) CA2232234A1 (2)
DE (1) DE69629576T2 (2)
TW (1) TW514667B (2)
WO (1) WO1997014805A2 (2)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE1006085A3 (fr) * 1992-07-31 1994-05-10 Univ Bruxelles Vecteur de clonage.
AU766257C (en) * 1998-05-07 2004-06-03 Universite Libre De Bruxelles Cytotoxin-based biological containment
WO2000028048A1 (en) * 1998-11-09 2000-05-18 Genecare Development Aps Novel plasmids for use in medicine and method of producing same
EP1135025B1 (en) * 1998-12-02 2007-04-25 University of Maryland, Baltimore Plasmid maintenance system for antigen delivery
US6413768B1 (en) 1998-12-02 2002-07-02 University Of Maryland Expression plasmids
US8076130B2 (en) * 1998-12-02 2011-12-13 University Of Maryland, Baltimore Plasmid maintenance system for antigen delivery
US6423545B1 (en) * 1999-07-08 2002-07-23 Albert Einstein College Of Medicine Of Yeshiva University Unmarked deletion mutants of mycobacteria and methods of using same
EP1111061A1 (en) * 1999-12-20 2001-06-27 Universite Libre De Bruxelles Double selection vector
US9012141B2 (en) * 2000-03-27 2015-04-21 Advaxis, Inc. Compositions and methods comprising KLK3 of FOLH1 antigen
US8470580B2 (en) * 2001-02-23 2013-06-25 Universite Libre De Bruxelles Method for the selection of recombination clones comprising a sequence encoding an antidote protein to a toxic molecule
US7396822B2 (en) * 2001-05-24 2008-07-08 Vaxiion Therapeutics, Inc. Immunogenic minicells and methods of use
US20030194798A1 (en) * 2001-05-24 2003-10-16 Surber Mark W. Minicell compositions and methods
US20030224369A1 (en) * 2002-02-25 2003-12-04 Surber Mark W. Reverse screening and target identification with minicells
US20030207833A1 (en) * 2002-02-25 2003-11-06 Neil Berkley Pharmaceutical compositions with minicells
US20030224444A1 (en) * 2002-02-25 2003-12-04 Sabbadini Roger A. Antibodies to native conformations of membrane proteins
US20050260585A1 (en) * 2002-03-19 2005-11-24 Cedric Szpirer Poison/antidote genetic systems for the selection of genetically modified eucaryote cells or organisms
US20040005700A1 (en) * 2002-05-28 2004-01-08 Surber Mark W. Poroplasts
US9309518B2 (en) 2002-09-03 2016-04-12 Universite Libre De Bruxelles Reversible, parallel and multitask cloning method and kit
WO2004022745A2 (en) * 2002-09-03 2004-03-18 Universite Libre De Bruxelles Reversible, parallel and multitask cloning method and kit
GB0327056D0 (en) * 2003-11-20 2003-12-24 Cobra Biolog Ltd Plasmid maintenance
WO2006055024A2 (en) * 2004-04-05 2006-05-26 Vaxiion Therapeutics, Inc. Minicells as vaccines
US8906664B2 (en) 2004-08-13 2014-12-09 The Trustees Of The University Of Pennsylvania Methods for constructing antibiotic resistance free vaccines
TWI311152B (en) * 2004-09-17 2009-06-21 Boehringer Ingelheim Rcv Gmbh & Co K Host-vector system for antibiotic-free cole1 plasmid propagation
CN1912127B (zh) * 2005-08-08 2011-05-25 百瑞全球有限公司 一种大肠杆菌表达载体及其应用
EP2152889B1 (en) 2007-05-29 2017-03-15 Nature Technology Corporation Vectors and methods for genetic immunization
US20120135033A1 (en) * 2008-05-19 2012-05-31 Anu Wallecha Multiple delivery system for heterologous antigens
US9017660B2 (en) 2009-11-11 2015-04-28 Advaxis, Inc. Compositions and methods for prevention of escape mutation in the treatment of Her2/neu over-expressing tumors
US9650639B2 (en) 2008-05-19 2017-05-16 Advaxis, Inc. Dual delivery system for heterologous antigens
US20110129499A1 (en) * 2008-05-19 2011-06-02 Paulo Maciag Dual delivery system for heterologous antigens
US10016617B2 (en) 2009-11-11 2018-07-10 The Trustees Of The University Of Pennsylvania Combination immuno therapy and radiotherapy for the treatment of Her-2-positive cancers
EP2498808A4 (en) * 2009-11-11 2014-01-08 Advaxis COMPOSITIONS AND METHOD FOR PREVENTING FLUID MUTATIONS IN THE TREATMENT OF TUMORS WITH HER2 / NEW OVEREXPRESSION
US9226958B2 (en) 2010-10-01 2016-01-05 University Of Georgia Research Foundation, Inc. Use of Listeria vaccine vectors to reverse vaccine unresponsiveness in parasitically infected individuals
ES2720659T3 (es) 2011-02-15 2019-07-23 Vaxiion Therapeutics Llc Composiciones terapéuticas y métodos para la administración dirigida, mediante minicélulas bacterianas, de moléculas bioactivas basadas en moléculas dirigidas que contienen Fc y anticuerpos
AU2012229218B2 (en) 2011-03-11 2017-03-02 Advaxis, Inc. Listeria-based adjuvants
CN104411327A (zh) 2012-03-12 2015-03-11 阿德瓦希斯公司 李斯特菌疫苗治疗以后的抑制细胞功能抑制
US9550998B2 (en) 2012-08-29 2017-01-24 Nature Technology Corporation DNA plasmids with improved expression
US20150322439A1 (en) 2012-11-19 2015-11-12 Nature Technology Corporation Replicative minicircle vectors with improved expression
WO2015024855A1 (en) 2013-08-19 2015-02-26 Syngulon Sa Controlled growth of microorganisms
WO2019057774A1 (en) 2017-09-19 2019-03-28 Deutsches Krebsforschungszentrum NON-INTEGRATING DNA VECTORS FOR THE GENETIC MODIFICATION OF CELLS
EP3456821B2 (en) 2017-09-19 2024-01-24 Deutsches Krebsforschungszentrum Non-integrating dna vectors for the genetic modification of cells
US11932672B2 (en) 2017-12-19 2024-03-19 Syngulon S.A. Fermentation process
WO2019183248A1 (en) 2018-03-21 2019-09-26 Nature Technology Corporation Viral and non-viral nanoplasmid vectors with improved production
WO2025160245A1 (en) 2024-01-25 2025-07-31 Aldevron, L.L.C. Viral and non-viral nanoplasmid vectors with improved production
WO2025231315A2 (en) 2024-05-03 2025-11-06 Aldevron, L.L.C. Bacterial host strains
WO2026076187A1 (en) 2024-10-03 2026-04-09 Aldevron, L.L.C. Compositions and methods for microbial production of antibiotic-free closed-ended linear dna

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4190495A (en) * 1976-09-27 1980-02-26 Research Corporation Modified microorganisms and method of preparing and using same
US4968619A (en) * 1976-09-27 1990-11-06 Research Corporation Modified microorganisms and method of preparing and using same
US4550081A (en) * 1980-05-19 1985-10-29 The Board Of Trustees Of The Leland Stanford Jr. University Non-reverting salmonella
US4837151A (en) * 1980-05-19 1989-06-06 The Board Of Trustees Of The Leland Stanford Junior University, Stanford University Live vaccines comprising two mutations and foreign antigen
US5077044A (en) * 1980-05-19 1991-12-31 The Board Of Trustees Of The Leland Stanford Jr. University Novel non-reverting shigella live vaccines
US4735801A (en) * 1982-09-07 1988-04-05 Board Of Trustees Of Leland Stanford Jr. University Novel non-reverting salmonella live vaccines
US5210035A (en) * 1980-05-19 1993-05-11 Board Of Trustees Of Leland Stanford Jr. University Non-reventing live vaccines
US4888170A (en) * 1981-10-22 1989-12-19 Research Corporation Vaccines obtained from antigenic gene products of recombinant genes
US5702916A (en) * 1982-09-16 1997-12-30 Gx Biosystems A/S Biological Containment
DK410783D0 (da) * 1982-09-16 1983-09-09 Benzon A Salfred Fremgangsmade til stabilisering af plasmider
FR2568891B1 (fr) * 1984-08-09 1988-05-27 Transgene Sa Procede de preparation d'une souche, notamment de levure, transformee par un vecteur d'expression, qui peut etre cultivee sur un milieu complet sans pression de selection et souche ainsi obtenue
DK594084A (da) * 1984-12-12 1986-06-13 Novo Industri As Fremgangsmaade til stabilisering af extra-chromosomale elementer i bakterier under dyrkning
GB2177097A (en) * 1985-06-18 1987-01-14 Genencor Inc Stable maintenance of nucleic acid in recombinant cells
DK275685D0 (da) * 1985-06-18 1985-06-18 Benzon As Alfred Stabilisering af biologiske systemer
US5387744A (en) * 1987-06-04 1995-02-07 Washington University Avirulent microbes and uses therefor: Salmonella typhi
IL86583A0 (en) * 1987-06-04 1988-11-15 Molecular Eng Ass Vaccine containing a derivative of a microbe and method for the production thereof
US5294441A (en) * 1987-06-04 1994-03-15 Washington University Avirulent microbes and uses therefor: salmonella typhi
ATE121785T1 (de) * 1987-10-07 1995-05-15 Univ Washington Verfahren zur erhaltung eines erwünschten rekombinanten gens in einer genetischen zellpopulation.
WO1990002484A1 (en) * 1988-09-06 1990-03-22 Washington University Oral immunization by transgenic plants
EP0465560B1 (en) * 1989-03-31 1996-06-05 Washington University VACCINES CONTAINING AVIRULENT phoP-TYPE MICROORGANISMS
IL93957A0 (en) * 1989-03-31 1990-12-23 Univ Washington Bordetella outer membrane proteins,their use in vaccines and their expression
WO1990011688A1 (en) * 1989-03-31 1990-10-18 Washington University Avirulent microbes and uses therefor
US5399346A (en) * 1989-06-14 1995-03-21 The United States Of America As Represented By The Department Of Health And Human Services Gene therapy
EP0500699B1 (en) * 1989-11-03 1998-06-10 Washington University Cross-protective salmonella vaccines
ATE177787T1 (de) * 1990-11-21 1999-04-15 Univ Washington Rekombinante avirulente salmonella antifruchtbarkeitsimpfstoffe
AU6705594A (en) * 1993-04-15 1994-11-08 Washington University Compositions of antigen containing recombinant salmonella, their use in anti-malarial vaccines and method for their preparation

Also Published As

Publication number Publication date
US5922583A (en) 1999-07-13
CA2232234A1 (en) 1997-04-24
DE69629576D1 (de) 2003-09-25
WO1997014805A2 (en) 1997-04-24
EP0856059B1 (en) 2003-08-20
TW514667B (en) 2002-12-21
AU7208896A (en) 1997-05-07
DE69629576T2 (de) 2004-06-24
JPH11513562A (ja) 1999-11-24
WO1997014805A3 (en) 1997-06-12
EP0856059A1 (en) 1998-08-05

Similar Documents

Publication Publication Date Title
ATE247713T1 (de) Verfahren zur herstellung von rekombinanten plasmiden
Nikolov et al. RNA polymerase II transcription initiation: a structural view
Sophianopoulou et al. Amino acid transporters of lower eukaryotes: regulation, structure and topogenesis
Shapiro et al. Dynamic spatial regulation in the bacterial cell
DE69633228D1 (de) Botulinumtoxinderivate die periferishe sensorische afferende funktionen ändern können
AU3559995A (en) Bilayer stabilizing components and their use in forming programmable fusogenic liposomes
WO1997014809A3 (en) Novel expression vectors and methods of use
DE69830312D1 (de) Methode zur spezifischen integration von genen in säugetierzellen durch homologe rekombination, und vektoren zu deren durchführung
BR9306289A (pt) Processo para produzir lactoferrina recombinante biologicamente ativa lactoferrina plasmídeo adotado para expressão em uma célula eucariótica célula eucariótica processo para produzir lactoferrina vetor de expressão recombinante e produto de proteína
Gluck V-ATPases of the plasma membrane
DE69632827D1 (de) Materialen und methoden im zusammenhang mit bindung und präsentation von substanzen auf zelloberflächen
DE69128893D1 (de) Genetische veränderung von endothelzellen
DE69431753D1 (de) Verfahren zur bereitung von liposomen mit gaseinschlüssen
ATE228856T1 (de) Mittel für die steuerung von der zellaktivität
HUP9900868A2 (hu) Heterológ gének kromoszomális expressziója bakteriális sejtekben
Koch On the growth and form of Escherichia coli
Wei et al. Footprints on the viral DNA ends in Moloney murine leukemia virus preintegration complexes reflect a specific association with integrase
AU2003222717A1 (en) Streptavidin-binding peptide
Lam et al. Enhancer-dependent 5′-splice site control of fruitless pre-mRNA splicing
Merrick Overview: mechanism of translation initiation in eukaryotes
TR200000288T2 (tr) İnsülin C-peptidin rekombinan ekspresyonu.
FI942442A0 (fi) Proteiinien tuotto 7B2-proteiinia käyttäen
AU1060397A (en) High efficiency tissue specific compound delivery system using streptavidin-protein a fusion protein
BG102355A (bg) Метод за стимулиране на клетъчно медиирани имунниотговори чрез насочване на определена генетична последователност
DE59508100D1 (de) Verwendung von zelladhäsions-peptiden zur modifikation des haftungsvermögens eukaryontischer zellen untereinander

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties